Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity
Proceedings of the National Academy of Sciences · 27.08.2024 · 121 (35)
DOI: 10.1073/pnas.2320189121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 21.08.2024. Verfasst von Fumiaki Mukohara und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Necrosis Factor alpha-Induced Protein 3. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS), Japan Agency for Medical Research and Development (AMED), MEXT | Japan Science and Technology Agency (JST).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) exert clinical efficacy against various types of cancers by reinvigorating exhausted CD8 + T cells that can expand and directly attack cancer cells (cancer-specific T cells) among tumor-infiltrating lymphocytes (TILs). Although some reports have identified somatic mutations in TILs, their effect on antitumor immunity remains unclear. In this study, we successfully established 18 cancer-specific T cell clones, which have an exhaustion phenotype, from the TILs of four patients with melanoma. We conducted whole-genome sequencing for these T cell clones and identified various somatic mutations in them with high clonality. Among the somatic mutations, an SH2D2A loss-of-function frameshift mutation and TNFAIP3 deletion could activate T cell effector functions in vitro. Furthermore, we generated CD8 + T cell–specific Tnfaip3 knockout mice and showed that Tnfaip3 function loss in CD8 + T cell increased antitumor immunity, leading to remarkable response to PD-1 blockade in vivo. In addition, we analyzed bulk CD3 + T cells from TILs in additional 12 patients and identified an SH2D2A mutation in one patient through amplicon sequencing. These findings suggest that somatic mutations in TILs can affect antitumor immunity and suggest unique biomarkers and therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
- Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama University, Okayama 700-8558, Japan.
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
- Department of Dermatology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
- Division of Cell Therapy, Chiba Cancer Research Institute, Chiba 260-8717, Japan.
- Department of Dermatology, University of Yamanashi, Yamanashi 409-3898, Japan.
ORCID-Profile: Fumiaki Mukohara, Takashi Inozume, Youki Ueda, Toshihide Ueno, Hideki Ikeda, Katsushige Kawase, Yuka Saeki, Shusuke Kawashima, Yasuhiro Nakamura, Hiroko Watanabe, Hiromichi Dansako, Tatsuyoshi Kawamura, Yutaka Suzuki, Hiroaki Honda, Masahito Kawazu, Yosuke Togashi
Förderung
- MEXT | Japan Society for the Promotion of Science (JSPS)
- Japan Agency for Medical Research and Development (AMED)
- MEXT | Japan Science and Technology Agency (JST)
- National Cancer Center Research and Development Fund
- Princess Takamatsu Cancer Research Fund
- Takeda Science Foundation (TSF)
- Naito Foundation ()
- Astellas Foundation for Research on Metabolic Disorders
Zitieren
APA
Mukohara, F., Iwata, K., Ishino, T., Inozume, T., Nagasaki, J., Ueda, Y., Suzawa, K., Ueno, T., Ikeda, H., Kawase, K., Saeki, Y., Kawashima, S., Yamashita, K., Kawahara, Y., Nakamura, Y., Honobe-Tabuchi, A., Watanabe, H., Dansako, H., Kawamura, T., …, & Togashi, Y. (2024). Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity. Proceedings of the National Academy of Sciences, 121(35). https://doi.org/10.1073/pnas.2320189121
Vancouver
Mukohara F, Iwata K, Ishino T, Inozume T, Nagasaki J, Ueda Y, et al. Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity. Proceedings of the National Academy of Sciences. 2024;121(35). doi:10.1073/pnas.2320189121
BibTeX
@article{Mukohara2024,
author = {Mukohara, Fumiaki and Iwata, Kazuma and Ishino, Takamasa and Inozume, Takashi and Nagasaki, Joji and Ueda, Youki and Suzawa, Ken and Ueno, Toshihide and Ikeda, Hideki and Kawase, Katsushige and Saeki, Yuka and Kawashima, Shusuke and Yamashita, Kazuo and Kawahara, Yu and Nakamura, Yasuhiro and Honobe-Tabuchi, Akiko and Watanabe, Hiroko and Dansako, Hiromichi and Kawamura, Tatsuyoshi and Suzuki, Yutaka and Honda, Hiroaki and Mano, Hiroyuki and Toyooka, Shinichi and Kawazu, Masahito and Togashi, Yosuke},
title = {Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {35},
doi = {10.1073/pnas.2320189121}
}
EUVIMED